▶︎Visit the Proteomics Analytics Resource Center: cst-science.com/e3znri
In this webinar, Jeffrey Silva, PhD, Principal Scientist in the Proteomics Group at Cell Signaling Technology, will provide an overview of how mass spectrometry-based proteomics can be used for drug discovery and development. Dr. Silva will also present several case studies highlighting how these techniques can be used to gain a deeper understanding of disease mechanisms and as a powerful tool for drug discovery.
0:00 Introduction
1:20 The Proteome is Highly Complex
2:40 About CST Proteomics Services
5:56 CST Proteomics: Sample Requirements
6:32 Global Protein Profiling
9:01 Post-Translational Modification Profiling
12:16 Organelle-Directed (i.e. Membrane Proteins)
13:29 ALK: Bench to Bedside
15:39 PTMScan Case Studies: Decrypting Drug Interactions
19:05 Dosing Fold-Change Volcano Plots
23:28 Time-Resolved Proteomics
26:11 Interrogating cAMP-Dependent Kinase Signaling
31:43 High-Throughput Ubiquitin Enrichment
34:38 CST Proteomics Services & Products Overview
36:27 What's the advantage of an antibody enrichment approach for biomarker discovery?
38:34 Recommendations to characterize series of drug candidates for targeted protein degradation?
41:16 Can CST services use FFPE clinical samples?
43:30 Is more sample needed to study multiple PTMs?
45:44 Can PTMScan increase the impact factor of a publication?
49:01 Strategy to compare secretome from varying cell number?
51:10 Any disadvantages of sequential enrichment?
54:08 Advantages of PTMScan vs global or IMAC methods?
About us: Cell Signaling Technology (CST) is a different kind of life sciences company-one founded, owned, and run by active research scientists, with the highest standards of product and service quality, technological innovation, and scientific rigor. We are a company of caring people driven by a devotion to facilitating good science-a company committed to doing the right thing for our Customers, our communities, and our planet. cellsignal.com/about
All trademarks are the property of their respective owners. For the latest trademark information, visit cellsignal.com/trademarks